臨床泌尿器科77巻11号

2023年10月発行

特集 どうする! 前立腺癌―多彩な治療薬をどう上手く使うか

〈mCRPCの薬物治療〉

前立腺の神経内分泌腫瘍：治療関連（誘導）型神経内分泌前立腺癌の特徴と治療

著者： 小坂威雄¹ 安水洋太¹

所属機関： ¹慶應義塾大学医学部泌尿器科学教室

ページ範囲：P.914 - P.918

文献概要

▶ポイント

・治療関連（誘導）型神経内分泌前立腺癌は強力なアンドロゲン受容体（AR）シグナル阻害薬の登場により出現した近年増加傾向にある新しい疾患概念である．

・臨床像として，急速進行の実質臓器転移やPSAが低く腫瘍量と比例しない症例で検出されやすく，ARの発現は不均一・PSA染色像でも発現が低い傾向にある脱分化型で，病理学的定義は明確ではない．

・確立された治療指針はなく，プラチナ系薬剤が選択されるが予後不良でアンメッドニーズであり，今後の開発が期待される．

参考文献

1） Beltran H, et al : Divergent Clonal Evolution of Castration-Resistant Neuroendocrine Prostate Cancer. Nat Med 22 : 298-305, 2016

2） Netto GJ, et al : The 2022 World Health Organization Classification of Tumors of the Urinary System and Male Genital Organs-Part B : Prostate and Urinary Tract Tumors. Eur Urol 82 : 469-482, 2022

3） Beltran H, et al : Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets. Cancer Discov 1 : 487-495, 2011

4） Epstein JI, et al : Proposed Morphologic Classification of Prostate Cancer with Neuroendocrine Differentiation. Am J Surg Pathol 38 : 756-767, 2014

5） Fine SW : Neuroendocrine Tumors of the Prostate. Mod Pathol 31 : S122-132, 2018

6） Aggarwal R, et al : Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer : A Multi-institutional Prospective Study. J Clin Oncol 36 : 2492-2503, 2018

7） Bluemn EG, et al : Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling. Cancer Cell 32 : 474-489.e6, 2017

8） Patel GK, et al : Neuroendocrine Differentiation of Prostate Cancer ― An Intriguing Example of Tumor Evolution at Play. Cancers （Basel） 11 : 1405, 2019

9） Chen R, et al : Molecular Model for Neuroendocrine Prostate Cancer Progression. BJU Int 122 : 560-570, 2018

10） Chedgy EC, et al : Biallelic Tumour Suppressor Loss and DNA Repair Defects in de novo Small-Cell Prostate Carcinoma. J Pathol 246 : 244-253, 2018

11） Katsui M, et al : Remarkable Response to Abiraterone Acetate in Castration-Resistant Prostate Cancer Patient with Aggressive Liver Metastasis. IJU Case Rep 2 : 12-14, 2019

12） Abida W, et al : Genomic Correlates of Clinical Outcome in Advanced Prostate Cancer. Proc Natl Acad Sci U S A 116 : 11428-11436, 2019

13） Conteduca V, et al : Clinical Features of Neuroendocrine Prostate Cancer. Eur J Cancer 121 : 7-18, 2019

14） Wang HT, et al : Neuroendocrine Prostate Cancer （NEPC） Progressing from Conventional Prostatic Adenocarcinoma : Factors Associated with Time to Development of NEPC and Survival from NEPC Diagnosis-A Systematic Review and Pooled Analysis. J Clin Oncol 32 : 3383-3390, 2014

15） Aparicio AM, et al : Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer. Clin Cancer Res 19 : 3621-3630, 2013

16） Beltran H, et al : A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer : Efficacy and Biomarkers. Clin Cancer Res 25 : 43-51, 2019

17） Corn PG, et al : Cabazitaxel plus Carboplatin for the Treatment of Men with Metastatic Castration-Resistant Prostate Cancers : A Randomised, Open-Label, Phase 1-2 Trial. Lancet Oncol 20 : 1432-1443, 2019

18） Puca L, et al : Delta-Like Protein 3 Expression and Therapeutic Targeting in Neuroendocrine Prostate Cancer. Sci Transl Med 11 : eaav0891, 2019

19） Baba Y, et al : Castration-Resistant Prostate Cancer Patient Presenting with Whole Genome Doubling with CDK-12 Mutation. BMC Med Genomics 15 : 32, 2022

20） Daimon T, et al : Prominent Response to Platinum-Based Chemotherapy in a Patient with BRCA2 Mutant-Neuroendocrine Prostate Cancer and MDM2 Amplification. IJU Case Rep 4 : 216-219, 2021

21） Hongo H, et al : Aggressive Prostate Cancer with Somatic Loss of the Homologous Recombination Repair Gene FANCA : A Case Report. Diagn Pathol 15 : 5, 2020

22） Hongo H, et al : Germline BRCA2 Mutation in a Case of Aggressive Prostate Cancer Accompanied by Spinal Bulbar Muscular Atrophy. Asian J Androl 24 : 116-118, 2022

23） Iwasawa T, et al : A Japanese Case of Castration-Resistant Prostate Cancer with BRCA2 and RB1 Co-Loss and TP53 Mutation : A Case Report. BMC Med Genomics 15 : 138, 2022

24） Izawa M, et al : Pulmonary Metastasis Secondary to Abiraterone-Resistant Prostate Cancer with Homozygous Deletions of BRCA2 : First Japanese Case. IJU Case Rep 4 : 14-17, 2021

25） Kobayashi H, et al : A First Case of Ductal Adenocarcinoma of the Prostate Having Characteristics of Neuroendocrine Phenotype with PTEN, RB1 and TP53 Alterations. BMC Med Genomics 14 : 245, 2021

26） Masuda T, et al : Multiple Metastases of Androgen Indifferent Prostate Cancer in the Urinary Tract : Two Case Reports and a Literature Review. BMC Med Genomics 15 : 118, 2022

27） Omura M, et al : First Successful Case of Platinum-Based Chemotherapy for Neuroendocrine Prostate Cancer with BRCA2 and PTEN Alterations. IJU Case Rep 5 : 41-44, 2021

28） Watanabe K, et al : Japanese Case of Enzalutamide-Resistant Prostate Cancer Harboring a SPOP Mutation With Scattered Allelic Imbalance : Response to Platinum-Based Therapy. Clin Genitourin Cancer 17 : e897-e902, 2019

29） Ku SY, et al : Rb1 and Trp53 Cooperate to Suppress Prostate Cancer Lineage Plasticity, Metastasis, and Antiandrogen Resistance. Science 355 : 78-83, 2017

30） Park JW, et al : Reprogramming Normal Human Epithelial Tissues to a Common, Lethal Neuroendocrine Cancer Lineage. Science 362 : 91-95, 2018

31） Dardenne E, et al : N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer. Cancer Cell 30 : 563-577, 2016

32） Yasumizu Y, et al : MUC1-C Regulates Lineage Plasticity Driving Progression to Neuroendocrine Prostate Cancer. Nat Commun 11 : 338, 2020

33） Tang F, et al : Chromatin Profiles Classify Castration-Resistant Prostate Cancers Suggesting Therapeutic Targets. Science 376 : eabe1505, 2022